United Therapeutics Corp’s recent filing unveils that its FOUNDER, CHAIRPERSON, AND CHIE ROTHBLATT MARTINE A acquired Company’s shares for reported $1.59 million on Sep 15 ’25. In the deal valued at $397.88 per share,4,000 shares were bought.
Then, ROTHBLATT MARTINE A bought 4,000 shares, generating $1,615,898 in total proceeds.
Before that, ROTHBLATT MARTINE A sold 4,000 shares. United Therapeutics Corp shares valued at $1,594,873 were divested by the Chairperson & CEO at a price of $398.72 per share. As a result of the transaction, ROTHBLATT MARTINE A now holds 130 shares, worth roughly $52404.3.
Cantor Fitzgerald initiated its United Therapeutics Corp [UTHR] rating to an Overweight in a research note published on June 02, 2025; the price target was $405. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who decreased its forecast for the stock in late April from “an Overweight” to “an Equal weight”. BofA Securities also remained covering UTHR and has increased its forecast on April 21, 2025 with a “Neutral” recommendation from previously “an Underperform” rating. Morgan Stanley revised its rating on July 11, 2024. It rated UTHR as “an Equal-weight” which previously was an “an Overweight”.
Price Performance Review of UTHR
On Monday, United Therapeutics Corp [NASDAQ:UTHR] saw its stock fall -0.47% to $403.11. Over the last five days, the stock has gained 2.15%. United Therapeutics Corp shares have risen nearly 16.44% since the year began. Nevertheless, the stocks have risen 14.25% over the past one year.
How much short interest is there in United Therapeutics Corp?
A steep rise in short interest was recorded in United Therapeutics Corp stocks on 2025-08-29, growing by 1.13 million shares to a total of 2.7 million shares. Yahoo Finance data shows the prior-month short interest on 2025-07-31 was 1.57 million shares. There was a rise of 41.88%, which implies that there is a positive sentiment for the stock.
